(Reuters) – Teva Pharmaceutical Industries Ltd (TEVA.TA) (TEVA.N) is shut to a deal to sell its women’s health assets outdoors the United States to personal fairness agency CVC Capital Partners, the Fly reported, citing Bloomberg.
The assets could possibly be valued at about $800 million, in accordance to the Bloomberg report. (bit.ly/2y03sQx)
Israel-based Teva, the world’s largest maker of generic medicine, has been taking a look at divestures to assist pare its $35 billion debt pile.
The firm on Monday agreed to sell its contraceptive model, Paragard, part of its women’s health enterprise, to a unit of Cooper Cos (COO.N) for $1.1 billion, on a day the corporate named business veteran Kare Schultz as CEO.
CVC Capital was not instantly obtainable for remark, whereas Teva stated it doesn’t reply to market rumors.
Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sriraj Kalluvila